论文部分内容阅读
目的观察干扰素联合炎琥宁治疗婴幼儿病毒性肺炎的临床效果。方法将96例婴幼儿病毒肺炎随机分成对照组(51例)和治疗组(45例),两组均给予抗生素防治感染及对症、支持等综合治疗,对照组在此基础上给予炎琥宁静滴,治疗组在对照组基础上给予重组人干扰素α1b肌肉注射,对比分析两组患者治疗情况。结果治疗组有效率88.9%,高于对照组的74.4%,组间差异有统计学意义(P<0.05)。治疗组症状、体征的消失时间较对照组缩短,差异有统计学意义(P<0.05)。结论应用重组人干扰素α1b联合炎琥宁治疗婴幼儿病毒性肺炎效果显著,值得临床推广应用。
Objective To observe the clinical efficacy of interferon combined with metronidazole in the treatment of infantile viral pneumonia. Methods Ninety-six cases of infantile virus pneumonia were randomly divided into control group (n = 51) and treatment group (n = 45). Both groups were given antibiotics to prevent and treat infection and symptomatic and supportive treatment. The control group was given Yanhuning intravenous infusion , The treatment group was given intramuscular injection of recombinant human interferon α1b on the basis of the control group, comparative analysis of the treatment of two groups of patients. Results The effective rate of the treatment group was 88.9%, which was higher than that of the control group (74.4%). The difference between the two groups was statistically significant (P <0.05). The disappearance time of symptoms and signs of the treatment group was shorter than that of the control group, with significant difference (P <0.05). Conclusion The application of recombinant human interferon α1b combined with mesylate treatment of infantile viral pneumonia is significant, worthy of clinical application.